Search research articles
Contact Us
Filters
Showing results (51-60 of 96) with videos related to
Page
of 10
Sort By:
Leukemia & Lymphoma
|
May 31, 2022
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study
Noémie Gadaud, Harmony Leroy, Emilie Bérard, et al.
Acta Haematologica
|
June 15, 2026
Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study
Edmond Chiche, Caroline Fileni, Sarah Bonnet, et al.
Blood Cancer Journal
|
November 14, 2021
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
Jean Galtier, Camille Alric, Emilie Bérard, et al.
Cancer Medicine
|
February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy
Harmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Alban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Blood Cancer Journal
|
July 9, 2023
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2<sup>V617F</sup> myeloproliferative neoplasms
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, et al.
Cancers
|
July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Annals of Hematology
|
January 25, 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
Ludovic Gabellier, Pierre Peterlin, Sylvain Thepot, et al.
Blood
|
July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
Marie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Oncotarget
|
October 31, 2015
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
Sarah Bertoli, Helena Boutzen, Laure David, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 96) with videos related to
Sort By:
Page
of 10
Leukemia & Lymphoma
|
May 31, 2022
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study
Noémie Gadaud, Harmony Leroy, Emilie Bérard, et al.
Acta Haematologica
|
June 15, 2026
Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study
Edmond Chiche, Caroline Fileni, Sarah Bonnet, et al.
Blood Cancer Journal
|
November 14, 2021
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
Jean Galtier, Camille Alric, Emilie Bérard, et al.
Cancer Medicine
|
February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy
Harmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Alban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Blood Cancer Journal
|
July 9, 2023
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2<sup>V617F</sup> myeloproliferative neoplasms
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, et al.
Cancers
|
July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Annals of Hematology
|
January 25, 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
Ludovic Gabellier, Pierre Peterlin, Sylvain Thepot, et al.
Blood
|
July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
Marie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Oncotarget
|
October 31, 2015
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
Sarah Bertoli, Helena Boutzen, Laure David, et al.
Page
of 10